Companion Animal Veterinary Vaccines Market Report 2025

This Companion Animal Veterinary Vaccines market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The companion animal veterinary vaccines market size has grown strongly in recent years. It will grow from $3.66 billion in 2024 to $3.88 billion in 2025 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to pet ownership growth, preventive healthcare, zoonotic diseases, advancements in vaccine technology.

The companion animal veterinary vaccines market size is expected to see strong growth in the next few years. It will grow to $5.09 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to increasing pet population, preventive healthcare awareness, technology and vaccine development, customized vaccination plans. Major trends in the forecast period include comprehensive vaccination programs, advanced vaccine technologies, vector-borne disease control, vaccination clinics and mobile services.

The growth of the companion animal veterinary vaccine market during the forecast period is driven by the increasing pet ownership among Gen X and Gen Y adults. According to the APPA, millennials (Gen Y) constitute the largest group of pet owners across different types of pets. Over 80% of Gen Y and Gen Z individuals own dogs, while fewer than 50% own cats. Additionally, the trend of multiple pet ownership is becoming increasingly common worldwide. For example, in 2022, as reported by Animal Medicines Australia, an Australia-based non-governmental organization, pet ownership in Australia saw significant growth. The number of pet owners reached 28,730.8 in 2022, compared to 39% in 2021, reflecting a 24% increase and a strong upward trend in pet adoption and care investment. This rise in pet ownership highlights the growing popularity of pets in Australian households and contributes to the expansion of the companion animal veterinary vaccine market.

The growth of the companion animal veterinary vaccines market is further driven by the increasing expenditure on pet health. Pet health is vital for the overall well-being of animals, including dogs, cats, birds, small mammals, and other domesticated pets. Regular vaccinations are a cornerstone of preventive pet healthcare, benefiting not only individual pet health but also the broader pet community. In June 2023, the American Pet Products Association reported that Americans spent $136.8 billion on pet health in 2022, representing a 10.68% increase from 2021, when spending amounted to $123.6 billion. Additionally, sales of pet food and treats accounted for $58.1 billion. This upward trajectory in pet health spending is propelling the growth of the companion animal veterinary vaccines market.

Companies operating in the companion animal veterinary vaccine industry are increasingly engaging in collaborations and partnerships to drive product innovations. To thrive in the competitive veterinary market, these companies are expanding into new geographic regions and developing innovative products by leveraging their skills and expertise through partnerships with other players. For example, Merck & Co.'s subsidiary, MSD Animal Health, has established a strategic partnership with Vinovo B.V., a division of Viscon Hatchery Automation, a leading hatchery automation company. This partnership aims to set a new standard in safe and effective Vinovo vaccination, enhancing bird welfare and reducing vaccine reactions.

Leading companies in the companion animal vaccine market are introducing innovative vaccines to enhance their market presence and revenue. For instance, in September 2022, Merck Animal Health (MSD Animal Health), a US-based animal pharmaceutical manufacturer, launched Nobivac Intra-Trac Oral BbPi, an oral vaccine designed to protect dogs against Bordetella bronchiseptica and canine parainfluenza virus. This groundbreaking vaccine, the first of its kind, provides mucosal immunity via the proprietary Immuno-Mist-R™ delivery system, ensuring comprehensive spray coverage. This innovation simplifies administration for veterinarians while improving comfort for dogs. Designed for dogs aged seven weeks and older, it is both thimerosal-free and preservative-free, prioritizing safety while streamlining the protection of canine respiratory health.

In June 2023, Mars Inc., a US-based manufacturing company, acquired Heska Corp. for $1.3 billion. This acquisition bolsters Mars Petcare's veterinary care offerings and underscores its commitment to advancing pet health. Heska is now integrated into Mars Petcare's science and diagnostics division, which includes Antech Diagnostics. This integration enhances diagnostic capabilities for veterinary professionals and pet owners by expanding access to advanced diagnostic technologies and accelerating research and development in veterinary healthcare. Heska Corp., a US-based veterinary services company, specializes in developing, manufacturing, and commercializing advanced veterinary diagnostics and vaccines for canine and feline health.

Companion animal vaccines are substances designed to stimulate the production of antibodies and confer immunity against one or more diseases in pets, including dogs, birds, and cats. They serve not only to protect against diseases but also to enhance food digestion, boost immunity, promote weight gain, and generate high-quality meat for commercial purposes.

The primary types of companion animal veterinary vaccines are inactivated, live attenuated, recombinant, and other products. Recombinant vaccines are created using recombinant DNA technology, involving the insertion of DNA encoding an antigen (e.g., a bacterial surface protein) into bacterial or mammalian cells, expression of the antigen within these cells, and subsequent purification. These products can be administered through oral, parenteral, and other routes of administration and are distributed through various channels, including veterinary hospitals, veterinary clinics, pharmacies, drug stores, and other distribution channels.

The companion animal veterinary vaccines research report is one of a series of new reports that provides companion animal veterinary vaccines statistics, including companion animal veterinary vaccines industry global market size, regional shares, competitors with companion animal veterinary vaccines share, detailed companion animal veterinary vaccines segments, market trends and opportunities, and any further data you may need to thrive in the companion animal veterinary vaccines industry. This companion animal veterinary vaccines research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the companion animal veterinary vaccines market include C.H. Boehringer Sohn AG & Co. KG, Eli Lilly and Company, Heska Corp., Merck and Co. Inc., Elanco Animal Health Incorporated, Zoetis Inc., Ceva Sante Animale SA, Bayer AG, Neogen Corporation, ImmuCell Corporation, Intervet Inc., Vetoquinol SA, IDEXX Laboratories Inc., Merial Inc., Biogenesis Bago SA, Hipra India Pvt. Ltd., Bimeda Animal Health Limited, Phibro Animal Health Corporation, Nexvet Biopharma plc, Bioniche Animal Health Canada Inc., Bioiberica S.A., Laboratorios Hipra S.A., Norbrook Laboratories Ltd., Dechra Pharmaceuticals PLC, Kyoritsu Seiyaku Corporation, VDS Pharma Animal Health, Kepro Technologies Private Limited, ECO Animal Health Group plc, Biostadt India Limited, bio-pharmaceutical company, Choong Ang Vaccine Laboratories Co. Ltd., CZ Veterinaria S.A.

North America was the largest region in the companion animal veterinary vaccines market in 2024. Asia-Pacific was the second-largest region in the companion animal veterinary vaccines market. The regions covered in the companion animal veterinary vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the companion animal veterinary vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The companion animal veterinary vaccine market consists of sales of toxoid vaccines, viral vector vaccines, messenger RNA vaccines, and conjugated vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.